Augusta University Research Institute Inc

1. GlaxoSmithKline, LLC. $593,971 78 payments
2. Novartis Pharmaceuticals Corporation $545,227 25 payments
3. Takeda Pharmaceuticals U.S.A., Inc. $525,082 50 payments
4. Pfizer Inc. $369,993 80 payments
5. Insmed, Inc. $315,909 387 payments
6. ViiV Healthcare Company $287,033 120 payments
7. AbbVie, Inc. $284,712 61 payments
8. EMD Serono, Inc. $268,514 45 payments
9. Amgen Inc. $265,221 4 payments
10. Sumitomo Pharma America, Inc. $245,473 35 payments

1. A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ All) $409,919 23 payments
2. A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab $392,166 19 payments
3. A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. $263,303 40 payments
4. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $232,973 34 payments
5. A Randomized, Double-Blind, Placebo Controlled, 3-Arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (Neptunus-2) $200,812 3 payments
6. A Phase 1B/2 Open-Label Trial of Tisotumab Vedotin Humax-Tf-Adc Monotherapy and in Combination With Other Agents in Subjects With Recurrent Or Stage Ivb Cervical Cancer $181,648 5 payments
7. Open-Label, Multicenter Phase 1/2 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors $168,293 1 payment
8. A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-042, An An $163,807 54 payments
9. A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact $160,722 51 payments
10. A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $159,032 51 payments

1. Other $35,890 5 payments
2. Non-patient care $12,669 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.